GH Research PLC (GHRS)

Market Cap	1.11B
Revenue (ttm)	n/a
Net Income (ttm)	-42.92M
Shares Out	62.03M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,831,265
Open	14.46
Previous Close	14.12
Day's Range	14.18 - 18.05
52-Week Range	7.98 - 20.50
Beta	0.99
Analysts	Strong Buy
Price Target	32.00 (+78.27%)
Earnings Date	Feb 26, 2026

About GHRS

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: GHRS
• Website: https://www.ghres.com

Analyst Summary

According to 10 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 78.27% from the latest price.

Price Target

$32.0

(78.27% upside)

Analyst Consensus: Strong Buy